Unit of Pediatrics, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy -
Unit of Pediatrics, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy.
Minerva Pediatr (Torino). 2021 Aug;73(4):294-300. doi: 10.23736/S2724-5276.18.05064-8. Epub 2018 Jul 2.
Topical corticosteroids (TCS) are the first-choice treatment for atopic dermatitis (AD) flares. In literature there are clear advice about the potency, dosage and frequency of application of TCS, but there are no shared indications about duration of the treatment during a flare. The aim of the study is to demonstrate if the use of a steroid cream for less than or 5 days, could be equal or more effective than the application for more than 5 days during a flare episode, in keeping a remission state of AD.
The study population (N.=122) was selected according to the following inclusion criteria: at least one specialist allergological and dermatological examination in the period November 2015 to February 2017, age between 1 and 11 years; mild to moderate atopic dermatitis. All patients were given a standardized telephone questionnaire, which concerns on multiple aspects: parents' self-reported perceptions of the severity of their child's condition; actual use of emollients, moisturizers and steroid creams; number of consecutive days of using of topical steroid cream during an exacerbation of AD; average number of AD exacerbations per month in the last year; total number of AD exacerbations in the last year.
Data from 96 patients was examined. We classified three groups of patients from data collected: group 1 (N.=40): use of TCS for ≤5 consecutive days during an exacerbation event of AD; group 2 (N.=12): use of TCS for >5 consecutive days during an exacerbation event of AD; group 3 (N.=44): nonuse of TCS or use of TCS with a different posology. We found a further subgroup in group 3 (3a, N.=27) with patients using only emollient crème in AD management. In group 1, 27 patients (67.5%) did not show a good AD control; on the contrary, 13 patients (27.5%) reported a good AD control. In group 2, 4 patients (25%) did not show a good AD control; on the contrary, 8 patients (75%) reported a good AD control. By comparing the data obtained in the presence of good AD control, the difference between the percentages obtained was found to be statistically significant (P=0.034).
The results obtained show that a therapeutic pattern based on the use of TCS for a duration of more than 5 consecutive days during an episode of AD exacerbation is more efficient than the proposed alternative therapeutic scheme in the maintenance of AD remission.
局部皮质类固醇(TCS)是特应性皮炎(AD)发作的首选治疗方法。文献中有关于 TCS 的强度、剂量和应用频率的明确建议,但对于在发作期间的治疗持续时间没有共同的指示。本研究的目的是证明在 AD 发作期间,使用皮质类固醇乳膏少于或 5 天,与使用超过 5 天相比,是否同样有效或更有效,以保持 AD 的缓解状态。
根据以下纳入标准选择研究人群(N=122):2015 年 11 月至 2017 年 2 月期间至少接受过一次专科过敏和皮肤科检查,年龄在 1 至 11 岁之间;轻度至中度特应性皮炎。所有患者均接受标准化电话问卷调查,涉及多个方面:父母对孩子病情严重程度的自我报告认知;实际使用保湿剂、润肤剂和皮质类固醇乳膏;AD 发作期间连续使用外用皮质类固醇乳膏的天数;过去一年中 AD 发作的平均每月次数;过去一年中 AD 发作的总次数。
检查了 96 名患者的数据。我们根据收集的数据将患者分为三组:组 1(N=40):AD 发作期间连续使用 TCS ≤5 天;组 2(N=12):AD 发作期间连续使用 TCS >5 天;组 3(N=44):未使用 TCS 或使用不同剂量的 TCS。我们在组 3 中发现了一个进一步的亚组(3a,N=27),其中患者仅在 AD 管理中使用保湿霜。在组 1 中,27 名患者(67.5%)未显示 AD 控制良好;相反,13 名患者(27.5%)报告 AD 控制良好。在组 2 中,4 名患者(25%)未显示 AD 控制良好;相反,8 名患者(75%)报告 AD 控制良好。通过比较良好 AD 控制所获得的数据,发现获得的百分比之间的差异具有统计学意义(P=0.034)。
研究结果表明,在 AD 发作期间,使用 TCS 的持续时间超过 5 天的治疗模式比维持 AD 缓解的替代治疗方案更有效。